Lucid Diagnostics

Lucid Diagnostics

Dr. Lishan Aklog co-founded Lucid Diagnostics in 2018 as a majority-owned subsidiary of PAVmed, a publicly traded medical device incubator he chairs. The firm operates as an independent public company, trading on the Nasdaq, rather than as a private family office. Its singular focus is the early detection of esophageal precancer and cancer, particularly targeting the millions of Americans with chronic gastroesophageal reflux disease (GERD) who face elevated risk. The company addresses a structural gap: endoscopy-based screening is too invasive and expensive for broad deployment, leaving a treatable condition dangerously underdiagnosed. Lucid's commercial engine is the EsoGuard Esophageal DNA Test, performed on cells collected via its companion EsoCheck Cell Collection Device. The test uses targeted bisulfite sequencing and machine learning to detect DNA methylation patterns associated with Barrett's Esophagus and esophageal adenocarcinoma. Deployment has concentrated on satellite testing sites called Lucid Test Centers, often co-located within gastroenterology practices and ambulatory surgery centers across the United States. In 2023, the firm secured foundational Medicare pricing and began processing a significant volume of tests at its centralized laboratory, marking its shift from pure R&D to commercial-stage diagnostics. While Lucid Diagnostics does not operate with a traditional family office's permanent capital pool, its financial architecture relies on the public equity markets and a research-backed commercial partnership with PAVmed, which retained a significant ownership stake post-spinout. Aklog, a board-certified cardiothoracic surgeon, directs strategy from the New York headquarters. The firm has expanded access through contracts with self-insured employers and large physician networks, building a revenue cycle around direct test sales. The executive roster includes Dennis M. McGrath as Chief Financial Officer, anchoring the finance function as the company scales its test volume. Lucid represents an unconventional entry in allocator conversations: a publicly traded operating company with a diagnostic-testing monopoly in a narrow therapeutic window. Its distinction lies in the PAVmed incubation model, which gives it a built-in clinical development pipeline and shared executive oversight rather than the standalone governance typical of a venture-backed health startup. This structure creates an unusual alignment dynamic for external investors evaluating its capital needs and growth trajectory.